BLA 021878 · Novo Nordisk
Levemir
Insulin Detemir · Injection
Last checked: Nov 20, 2026Latest source record: Oct 19, 2005 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Oct 19, 2005
Approved uses
1
Original approval plus efficacy supplements
Registered trials
170
55 Phase 3, 4 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- LEVEMIR · INSULIN DETEMIR 100 UNITS/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Detemir" as an intervention, any sponsor and status, largest first.
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT00264901 · 5,652 participants · Start Oct 2005 · Primary completion Nov 2006
Drug: insulin detemir · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Plainsboro, New Jersey
- A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT02451137 · 3,304 participants · Start Jun 16, 2015 · Primary completion Mar 2, 2018
Drug: Insulin glargine, 300 U/ml; Insulin glargine, 100 U/ml and 2 more · For: Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Gulf Shores, Alabama; Guntersville, Alabama · 427 sites in all
- Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes MellitusPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01709929 · 2,287 participants · Start Oct 2005 · Primary completion Apr 2006
Drug: insulin detemir · For: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Sites: Mississauga, Canada
- DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational DiabetesPivotal-lookingRecruiting
Ohio State UniversityAcademic, hospital or other
NCT06445946 · 1,572 participants (planned) · Start Aug 1, 2024 · Primary completion Dec 2029
Drug: Metformin; Insulin · For: Gestational Diabetes Mellitus; Pregnancy, High Risk
Sites: Tuscaloosa, Alabama; Los Angeles, California; San Francisco, California · 26 sites in all
- Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01831765 · 1,290 participants · Start Aug 26, 2013 · Primary completion May 12, 2015
Drug: Faster-acting insulin aspart; insulin detemir and 2 more · For: Diabetes; Diabetes Mellitus, Type 1
Sites: Mobile, Alabama; Tucson, Arizona; Anaheim, California · 191 sites in all
- The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT00856986 · 987 participants · Start Mar 2009 · Primary completion Apr 2010
Drug: liraglutide; insulin detemir and 1 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Alexander City, Alabama; Birmingham, Alabama; Encino, California · 233 sites in all
- Lantus Versus Levemir Treat-To-TargetPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00405418 · 973 participants · Start Nov 2006 · Primary completion Jun 2008
Drug: Insulin glargine; Insulin Detemir · For: Diabetes Mellitus, Type 2
Sites: North Ryde, Australia; São Paulo, Brazil; Laval, Canada · 20 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Levemir (Insulin Detemir)
2024 spending
$30.6M
Beneficiaries
48,292
142,657 claims
Per beneficiary
$634
$10.38 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $436,907,523 |
| 2021 | $373,910,077 |
| 2022 | $319,727,025 |
| 2023 | $287,253,250 |
| 2024 | $30,621,217 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
Dehghani M, Sadeghi M, Barzkar F, et al. · Front Endocrinol (Lausanne) 2024 · Systematic Review, Network Meta-Analysis
- Costs associated with long-acting insulin analogues in patients with diabetes.
Alemayehu B, Speiser J, Bloudek L, et al. · Am J Manag Care 2018 · Comparative Study, Research Support, Non-U.S. Gov't
- Safety and efficacy of insulin detemir versus NPH in the treatment of diabetes during pregnancy: Systematic review and meta-analysis of randomized controlled trials.
Athanasiadou KI, Paschou SA, Stamatopoulos T, et al. · Diabetes Res Clin Pract 2022 · Meta-Analysis, Systematic Review
- Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an openߛlabel, multinational, randomised, controlled, non-inferiority trial.
Mathiesen ER, Alibegovic AC, Corcoy R, et al. · Lancet Diabetes Endocrinol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Metformin for gestational diabetes study: metformin vs insulin in gestational diabetes: glycemic control and obstetrical and perinatal outcomes: randomized prospective trial.
Picón-César MJ, Molina-Vega M, Suárez-Arana M, et al. · Am J Obstet Gynecol 2021 · Multicenter Study, Randomized Controlled Trial
- Efficacy and safety of insulin detemir versus glargine in patients with diabetes: a systematic review and meta-analysis.
Rezaei S, Taheri A, Taheri S, et al. · Expert Rev Clin Pharmacol 2022 · Meta-Analysis, Systematic Review
Sponsor: Novo Nordisk
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.